139 related articles for article (PubMed ID: 16648505)
1. Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.
Tolcher AW; Hao D; de Bono J; Miller A; Patnaik A; Hammond LA; Smetzer L; Van Wart Hood J; Merritt J; Rowinsky EK; Takimoto C; Von Hoff D; Eckhardt SG
J Clin Oncol; 2006 May; 24(13):2052-8. PubMed ID: 16648505
[TBL] [Abstract][Full Text] [Related]
2. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.
Parker LP; Wolf JK; Price JE
Ann Clin Lab Sci; 2000 Oct; 30(4):395-405. PubMed ID: 11045764
[TBL] [Abstract][Full Text] [Related]
4. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus.
Zhang WW; Fang X; Mazur W; French BA; Georges RN; Roth JA
Cancer Gene Ther; 1994 Mar; 1(1):5-13. PubMed ID: 7621238
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma.
Shimada H; Matsubara H; Shiratori T; Shimizu T; Miyazaki S; Okazumi S; Nabeya Y; Shuto K; Hayashi H; Tanizawa T; Nakatani Y; Nakasa H; Kitada M; Ochiai T
Cancer Sci; 2006 Jun; 97(6):554-61. PubMed ID: 16734736
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a real-time PCR assay for the detection and quantitation of p53 recombinant adenovirus in clinical samples from patients treated with Ad5CMV-p53 (INGN 201).
Saulnier P; Vidaud M; Gautier E; Motté N; Bellet D; Escudier B; Wilson D; Yver A
J Virol Methods; 2003 Dec; 114(1):55-64. PubMed ID: 14599679
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer.
Fujiwara T; Tanaka N; Kanazawa S; Ohtani S; Saijo Y; Nukiwa T; Yoshimura K; Sato T; Eto Y; Chada S; Nakamura H; Kato H
J Clin Oncol; 2006 Apr; 24(11):1689-99. PubMed ID: 16505415
[TBL] [Abstract][Full Text] [Related]
8. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic effects of Ad5CMV-p53 expression in two human nasopharyngeal carcinoma cell lines.
Li JH; Li P; Klamut H; Liu FF
Clin Cancer Res; 1997 Apr; 3(4):507-14. PubMed ID: 9815713
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
[TBL] [Abstract][Full Text] [Related]
11. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.
Lang FF; Yung WK; Raju U; Libunao F; Terry NH; Tofilon PJ
J Neurosurg; 1998 Jul; 89(1):125-32. PubMed ID: 9647183
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53.
Wang J; Bucana CD; Roth JA; Zhang WW
Cancer Gene Ther; 1995 Mar; 2(1):9-17. PubMed ID: 7621257
[TBL] [Abstract][Full Text] [Related]
14. Safety evaluation of Ad5CMV-p53 in vitro and in vivo.
Zhang WW; Alemany R; Wang J; Koch PE; Ordonez NG; Roth JA
Hum Gene Ther; 1995 Feb; 6(2):155-64. PubMed ID: 7734516
[TBL] [Abstract][Full Text] [Related]
15. Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells.
Sasaki R; Shirakawa T; Zhang ZJ; Tamekane A; Matsumoto A; Sugimura K; Matsuo M; Kamidono S; Gotoh A
Int J Radiat Oncol Biol Phys; 2001 Dec; 51(5):1336-45. PubMed ID: 11728695
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for bladder cancer using adenoviral vector.
Wada Y; Gotoh A; Shirakawa T; Hamada K; Kamidono S
Mol Urol; 2001; 5(2):47-52. PubMed ID: 11690547
[TBL] [Abstract][Full Text] [Related]
17. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach.
Cristofanilli M; Krishnamurthy S; Guerra L; Broglio K; Arun B; Booser DJ; Menander K; Van Wart Hood J; Valero V; Hortobagyi GN
Cancer; 2006 Sep; 107(5):935-44. PubMed ID: 16874816
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers.
Gotoh A; Kao C; Ko SC; Hamada K; Liu TJ; Chung LW
J Urol; 1997 Aug; 158(2):636-41. PubMed ID: 9224383
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas.
Bao JJ; Zhang WW; Kuo MT
Hum Gene Ther; 1996 Feb; 7(3):355-65. PubMed ID: 8835222
[TBL] [Abstract][Full Text] [Related]
20. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma.
Li JH; Lax SA; Kim J; Klamut H; Liu FF
Int J Radiat Oncol Biol Phys; 1999 Feb; 43(3):607-16. PubMed ID: 10078646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
